This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.
Amarin (AMRN) Meets Earnings Estimates in Q1, Revenues Tops
by Zacks Equity Research
Amarin's (AMRN) first quarter earnings were in line with expectations. However, sales beats estimates. Stock down.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
Is Amarin (AMRN) Stock a Solid Choice Right Now?
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin's Stock Plunges Following Unfavorable Patent Ruling
by Zacks Equity Research
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $18.72, moving -0.58% from the previous trading session.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $19.40 in the latest trading session, marking a +0.41% move from the prior day.
AstraZeneca to End Phase III Study on Fish Oil Heart Drug
by Zacks Equity Research
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
by Zacks Equity Research
AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.
BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Applied Therapeutics Up on Positive Galactosemia Study Data
by Zacks Equity Research
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease
by Zacks Equity Research
Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.
Why Amarin (AMRN) Stock Might be a Great Pick
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.
aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma
by Zacks Equity Research
aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $21.23, marking a +1.34% move from the previous day.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day